# EDGAR Filing Document

**Accession Number:** 0001609550
**File Stem:** 0001609550-26-000030
**Filing Date:** 2026-5
**Character Count:** 19622
**Document Hash:** d70434aced284000d5b7f4880e724865
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001609550-26-000030.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001609550-26-000030

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**REFERENCES 429**: 333-224731

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inspire Medical Systems, Inc.
- **CENTRAL INDEX KEY:** 0001609550
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 261377674
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295626
- **FILM NUMBER:** 26951946

**BUSINESS ADDRESS:**
- **STREET 1:** 5500 WAYZATA BLVD
- **STREET 2:** SUITE 1600
- **CITY:** GOLDEN VALLEY
- **STATE:** MN
- **ZIP:** 55416
- **BUSINESS PHONE:** 763-957-5037

**MAIL ADDRESS:**
- **STREET 1:** 5500 WAYZATA BLVD
- **STREET 2:** SUITE 1600
- **CITY:** GOLDEN VALLEY
- **STATE:** MN
- **ZIP:** 55416

**As filed with the United States Securities and Exchange Commission on May 7, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**Under**

**THE SECURITIES ACT OF 1933**

**INSPIRE MEDICAL SYSTEMS, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **Delaware** | **26-1377674** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

**5500 Wayzata Blvd., Suite 1600**

**Golden Valley, MN 55416** 

(Address of Principal Executive Offices) (Zip Code)

**INSPIRE MEDICAL SYSTEMS, INC. AMENDED AND RESTATED 2018 INCENTIVE AWARD PLAN**

(Full Title of the Plan)

**Timothy P. Herbert**

**President and Chief Executive Officer**

**5500 Wayzata Blvd., Suite 1600**

**Golden Valley, MN 55416** 

(Name and Address of Agent for Service)

**(844) 672-4357**

(Telephone Number, including Area Code, of Agent for Service)

**Copies to:**

**B. Shayne Kennedy**

**Nathan Ajiashvili**

Latham & Watkins LLP

650 Town Center Drive, 20th Floor

Costa Mesa, CA 92626

(714) 540-1235

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | □ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 is being filed for the purpose of registering 2,600,000 shares of the Registrant's common stock, par value $0.001 per share, to be issued pursuant to the Inspire Medical Systems, Inc. Amended and Restated 2018 Incentive Award Plan (the "***A&R Plan***"). On April 30, 2026, the Registrant's stockholders approved the amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan (the "***2018 Plan***") to, among other things, authorize the issuance of 9,903,857 shares of the Registrant's common stock for awards under the A&R Plan, which includes 7,303,857 shares previously authorized for issuance under the 2018 Plan plus an increase of 2,600,000 shares, and extend the term of the 2018 Plan to March 6, 2036.

**INCORPORATION BY REFERENCE OF CONTENTS OF** 

**REGISTRATION STATEMENTS ON FORM S-8** 

The contents of the Registration Statement on Form S-8 (File No. <u>[333-224731](https://www.sec.gov/Archives/edgar/data/1609550/000110465918031004/a18-12535_1s8.htm)</u>), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the A&R Plan (as an amendment and restatement of the 2018 Plan), are incorporated by reference herein.

**Item 8. Exhibits.**

The following documents are filed as exhibits to this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit Number** | **Description of Exhibit** |
| 4.1 | <u>[Seventh Amended and Restated Certificate of Incorporation of Inspire Medical Systems, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-38468) filed on May 7, 2018)](https://www.sec.gov/Archives/edgar/data/1609550/000110465918030910/a18-13039_1ex3d1.htm)</u> |
| 4.2 | <u>[Certificate of Amendment to the Seventh Amended and Restated Certificate of Incorporation of Inspire Medical Systems, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q (File No. 001-38468) filed on May 4, 2026)](https://www.sec.gov/Archives/edgar/data/1609550/000160955026000023/ex32certificateofamendme.htm)</u> |
| 4.3 | <u>[Amended and Restated Bylaws of Inspire Medical Systems, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-38468) filed on February 11, 2026)](https://www.sec.gov/Archives/edgar/data/1609550/000160955026000012/ex31_amendedxrestatedbyl.htm)</u> |
| 4.4 | <u>[Form of Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1 (File No. 333-224176) filed on April 23, 2018)](https://www.sec.gov/Archives/edgar/data/1609550/000104746918003044/a2235314zex-4_1.htm)</u> |
| 10.1 | <u>[Inspire Medical Systems, Inc. Amended and Restated 2018 Incentive Award Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-38468) filed on May 5, 2026)](https://www.sec.gov/Archives/edgar/data/1609550/000160955026000026/ex101insp-aandr2018incen.htm)</u> |
| 5.1\* | <u>[Opinion of Latham & Watkins LLP, counsel to the Registrant](exh5insp-2026sx8arplanxo.htm)</u> |
| 23.1\* | <u>[Consent of Ernst & Young LLP, independent registered public accounting firm for Inspire Medical Systems, Inc.](eyconsent.htm)</u> |
| 23.3\* | <u>[Consent of Latham & Watkins LLP (contained in Exhibit 5.1)](exh5insp-2026sx8arplanxo.htm)</u> |
| 24.1\* | Powers of Attorney (included on the signature page of the Registration Statement) |
| 107\* | <u>[Filing Fee Table](exfilingfees.htm)</u> |

---

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Golden Valley, State of Minnesota, on this 7th day of May, 2026.

---

| | |
|:---|:---|
| | **INSPIRE MEDICAL SYSTEMS, INC.** |
| By: | /s/ Timothy P. Herbert |
|  | Timothy P. Herbert |
|  | *Chief Executive Officer and President* |

---

**POWER OF ATTORNEY**

&nbsp;&nbsp;&nbsp;&nbsp;*KNOW ALL PERSONS BY THESE PRESENTS*, that each person whose signature appears below hereby constitutes and appoints Timothy P. Herbert and Matthew J. Osberg, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Timothy P. Herbert | Chief Executive Officer (principal executive officer), President and Chair of the Board of Directors | May 7, 2026 |
| Timothy P. Herbert | Chief Executive Officer (principal executive officer), President and Chair of the Board of Directors |  |
| /s/ Matthew J. Osberg | Chief Financial Officer (principal financial and accounting officer) | May 7, 2026 |
| Matthew J. Osberg | Chief Financial Officer (principal financial and accounting officer) |  |
| /s/ Shelley G. Broader |  | May 7, 2026 |
| Shelley G. Broader | Director |  |
| /s/ Cynthia B. Burks |  | May 7, 2026 |
| Cynthia B. Burks | Director |  |
| /s/ Myriam J. Curet, M.D. |  | May 7, 2026 |
| Myriam J. Curet, M.D. | Director |  |
| /s/ Gary L. Ellis |  | May 7, 2026 |
| Gary L. Ellis | Director |  |
| /s/ Georgia Melenikiotou |  | May 7, 2026 |
| Georgia Melenikiotou | Director |  |
| /s/ Dana G. Mead, Jr. |  | May 7, 2026 |
| Dana G. Mead, Jr. | Director |  |
| /s/ Shawn T McCormick |  | May 7, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| Shawn T McCormick | Director | |
| /s/ Casey Tansey | | May 7, 2026 |
| Casey Tansey | Director | |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Inspire Medical Systems, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.001 par value per share | 457(a) | 2600000 | $46.40 | $120640000.00 | 0.0001381 | $16660.38 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $120640000.00  |  | $16660.38  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $16660.38  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) In accordance with Rule 416(b) under the Securities Act of 1933, as amended (the "Securities Act"), the shares of common stock, par value $0.001 per share (the " Common Stock"), of Inspire Medical Systems, Inc. (the "Registrant") being registered hereunder include such indeterminate number of shares of the Common Stock as may be issuable with respect to the shares of the Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions. (2) Consists of 2,600,000 shares of the Registrant's Common Stock authorized for issuance under the Inspire Medical Systems, Inc. Amended and Restated 2018 Incentive Award Plan (the "A&R Plan"). (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based upon the average of the high and low prices of the Registrant's Class A Common Stock on May 5, 2026 as reported on the New York Stock Exchange. (4) The Registrant does not have any fee offsets.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---

## Exhibit 5.1

![](exh5insp-2026sx8arplanxo001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;US-DOCS\171256526.2 1271 Avenue of the Americas New York, New York 10020-1401 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid Washington, D.C. May 7, 2026 Inspire Medical Systems, Inc. 5500 Wayzata Blvd., Suite 1600 EXHIBIT 5.1 Golden Valley, MN, 55416 Re: Registration Statement on Form S-8; 2,600,000 shares of Inspire Medical Systems, Inc. Common Stock, $0.001 par value per share To the addressee set forth above: We have acted as special counsel to Inspire Medical Systems, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing by the Company with the Securities and Exchange Commission (the "Commission") of a registration statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Act"), relating to the issuance by the Company of up to 2,600,000 shares of common stock of the Company, $0.001 par value per share (the "Shares"), issuable under the Inspire Medical Systems, Inc. Amended and Restated 2018 Incentive Award Plan (the "Plan"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the prospectus forming a part thereof, other than as expressly stated herein with respect to the issuance of the Shares. As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the "DGCL"), and we express no opinion with respect to any other laws. Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company for legal consideration in excess of par value in the circumstances contemplated by the Plan, assuming in each case that the individual grants or awards under the Plan are duly

------

![](exh5insp-2026sx8arplanxo002.jpg)

May 7, 2026 Page 2 US-DOCS\171256526.2 authorized by all necessary corporate action and duly granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. Sincerely, /s/ Latham & Watkins LLP

------

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Inspire Medical Systems, Inc. Amended and Restated 2018 Incentive Award Plan (the "A&R Plan") of our reports dated December 31, 2025, with respect to the consolidated financial statements of Inspire Medical Systems, Inc. and the effectiveness of internal control over financial reporting of Inspire Medical Systems, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Minneapolis, Minnesota

May 7, 2026

<br>